Multidimensional Proteomics Analysis of Amniotic Fluid to Provide Insight into the Mechanisms of Idiopathic Preterm Birth by Buhimschi, Irina A. et al.
Multidimensional Proteomics Analysis of Amniotic Fluid
to Provide Insight into the Mechanisms of Idiopathic
Preterm Birth
Irina A. Buhimschi, Guomao Zhao, Victor A. Rosenberg, Sonya Abdel-Razeq, Stephen Thung, Catalin S.
Buhimschi*
Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut, United States of America
Abstract
Background: Though recent advancement in proteomics has provided a novel perspective on several distinct pathogenetic
mechanisms leading to preterm birth (inflammation, bleeding), the etiology of most preterm births still remains elusive. We
conducted a multidimensional proteomic analysis of the amniotic fluid to identify pathways related to preterm birth in the
absence of inflammation or bleeding.
Methodology/Principal Findings: A proteomic fingerprint was generated from fresh amniotic fluid using surface-enhanced
laser desorbtion ionization time of flight (SELDI-TOF) mass spectrometry in a total of 286 consecutive samples retrieved from
women who presented with signs or symptoms of preterm labor or preterm premature rupture of the membranes.
Inflammation and/or bleeding proteomic patterns were detected in 32% (92/286) of the SELDI tracings. In the remaining
tracings, a hierarchical algorithm was applied based on descriptors quantifying similarity/dissimilarity among proteomic
fingerprints. This allowed identification of a novel profile (Q-profile) based on the presence of 5 SELDI peaks in the 10–
12.5 kDa mass area. Women displaying the Q-profile (mean6SD, gestational age: 2564 weeks, n=40) were more likely to
deliver preterm despite expectant management in the context of intact membranes and normal amniotic fluid clinical
results. Utilizing identification-centered proteomics techniques (fluorescence two-dimensional differential gel electropho-
resis, robotic tryptic digestion and mass spectrometry) coupled with Protein ANalysis THrough Evolutionary Relationships
(PANTHER) ontological classifications, we determined that in amniotic fluids with Q-profile the differentially expressed
proteins are primarily involved in non-inflammatory biological processes such as protein metabolism, signal transduction
and transport.
Conclusion/Significance: Proteomic profiling of amniotic fluid coupled with non-hierarchical bioinformatics algorithms
identified a subgroup of patients at risk for preterm birth in the absence of intra-amniotic inflammation or bleeding,
suggesting a novel pathogenetic pathway leading to preterm birth. The altered proteins may offer opportunities for
therapeutical intervention and future drug development to prevent prematurity.
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Introduction
Prematurity remains the leading cause of early neonatal deaths
and long term neuro-developmental handicap [1,2]. Despite
extensive research and a variety of interventions and preventive
strategies, the rate of preterm birth has steadily increased over the
past 20 years to reach a high of 12.8 percent (%) in 2005 [3].
Several pathophysiological mechanisms have been implicated in
triggering preterm birth [4]. Of these, genetic predisposition, fetal
stress, excessive stretching, inflammation/ infection and decidual
hemorrhage have received increased attention. [4]
In prior studies we concentrated our attention on investigating
the changes in amniotic fluid proteome in the context of
inflammation and decidual hemorrhage induced-preterm birth
[5,6] We devised a novel, stepwise strategy to extract relevant
proteomic biomarkers based on filter preferences applied sequen-
tially. This strategy was named ‘‘Mass restricted scoring or MR
scoring’’ [5]. Based on these principles we defined relevant disease
biomarker patterns characteristic for intra-amniotic inflammation
and decidual bleeding [5,6]. Proteomic identification techniques
recognized the four protein biomarkers (which comprise the
proteomic profile or MR score characteristic for intra-amniotic
inflammation) as neutrophil defensin-2, neutrophil defensin-1,
calgranulin C and calgranulin A. A combination of peaks
corresponding to free hemoglobin (Hb) chains was component of
the proteomic pattern characteristic for decidual hemorrhage [6].
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pattern in amniotic fluid proved to be predictive not only for
preterm birth but also for histological funisitis and early onset
neonatal sepsis [7,8]. Regrettably, notwithstanding recent ad-
vancements in comprehending the pathophysiology of preterm
birth, the etiology of this syndrome still remains unknown [9].
The transition from the past era of hypothesis-driven research to
that of a discovery-determined one stemmed from opportunities
presented by the contemporaneous revolution in biomedical
sciences such as the one recently witnessed in proteomics [10].
Proteomics seems to have all the attributes necessary to provide
the needed breakthrough in understanding the physiopathology of
idiopathic preterm birth and to identify novel inroads to help
prevent its occurrence. To that end we expect that causes other
that inflammation and bleeding would also generate aberrant
amniotic fluid protein expression levels that translate in charac-
teristic proteomic signatures related to the underlying cause. The
objective of our study was to identify biomarker patterns relating
to preterm birth in the absence of inflammation or bleeding and
provide a comprehensive analysis of the amniotic fluid proteome
in cases with such abnormal patterns.
Methods
Study population
We conducted a prospective study that included 285 women
recruited following admission to the Labor and Birth unit or High
Risk antepartum units at Yale New Haven Hospital (YNHH).
Symptoms of preterm labor, preterm premature rupture of
membranes (PPROM), advanced cervical dilatation ($3 centime-
ters) and/or uterine contractions unresponsive to tocolysis were
considered clinical indications for ultrasound-guided amniocentesis
to rule-out infection. Women were enrolled consecutively based on
a protocol approved by the Human Investigation Committee of
Yale University. Written informed consent for the use of biological
samples was obtained prior to the procedure. All women in this
study had a singleton fetus at ,37 weeks gestational age. Exclusion
criteria included: viral infections (human immunodeficiency virus or
hepatitis), anhydramnios and presence of fetal heart rate abnor-
malities (bradycardia, recurrent variable and late decelerations)
requiring emergency intervention. Gestational age was established
based on a second trimester ultrasonographic examination prior to
20 weeks in all instances. We defined preterm labor as presence of
regular uterine contractions accompanied by cervical effacement
and/or dilatation in patients ,37 weeks gestational age. The
diagnosis of PPROM was confirmed by vaginal amniotic fluid
‘‘pooling’’, ‘‘nitrazine’’, ‘‘ferning’’ or by an amniocentesis-dye
positive test. Clinical chorioamnionitis was suspected in the
presence of either fever .38uCelsius (C), uterine tenderness or
fetal tachycardia. The decision to perform an amniocentesis and
patient management including the decision to deliver the fetus were
at the discretion of the clinical team independent of our study
protocol. Patients received steroids for enhancement of fetal lung
maturity if gestational age was between 24 and 32 weeks. Antibiotic
therapy was initiated as per the usual PPROM protocol (ampicillin
and erythromycin i.v. in the first 48 hours, followed thereafter by
oral medication) [11]. After amniocentesis, all participants were
followed prospectively to the point of delivery. We recorded
whether preterm delivery of the fetus occurred subsequent to
spontaneous onset of uterine contractions or secondary to a
clinically indicated delivery aimed to deliver the fetus in the absence
of uterine contractions (including gestational age .34 weeks,
evidence of intra-amniotic infection, prolapsed cord, non-reassuring
fetal heart rate) [12].
Following retrieval, amniotic fluid was cultured for aerobic and
anaerobic bacteria, Ureaplasma and Mycoplasma species by the
YNHH microbiology laboratory. The clinical laboratory tests
performed for the purpose of diagnosing inflammation/infection
were: glucose, lactate dehydrogenase (LDH), Gram stain, white
(WBC) and red blood cell (RBC) counts. Research samples were
spun at 30006ga t4 uC for 20 min., aliquoted and stored at –80uC
for further study.
Proteomic profiling for identification of patterns of intra-
amniotic inflammation (MR score) and bleeding
We used surface-enhanced laser desorbtion ionization time-of-
flight (SELDI-TOF) mass spectrometry to screen for the presence
of biomarkers characteristic of inflammation and bleeding in fresh
samples of amniotic fluid. The results were not made available to
the clinical management team. The methodology for generation of
the MR score and identification of bleeding biomarkers has been
previously described [5,6]. Briefly, 5 microliters (mL) of 10-fold
diluted amniotic fluid in phosphate-buffered saline solution (PBS)
was placed on spots of duplicate H4 arrays (8-spot H4 array;
Ciphergen Biosystems). After 1-hour incubation, the sample was
aspirated, and the spots individually washed with 20% aqueous
acetonitrile solution, air-dried, and covered with energy absorbing
molecule (EAM) matrix solution of either 1-mL of 20% saturated
a-cyano-4-hydroxycinnamic acid (CHCA) in 0.5% trifluoroacetic
acid/50% acetonitrile on one array, or 2 sequential applications of
1-mL 50% saturated solution (in 0.5% trifluoroacetic acid/50%
acetonitrile) of sinapinic acid (SPA) on the other. The proteomic
arrays were read in the the ProteinChip Reader (model PBS II;
Ciphergen Biosystems) using the ProteinChip software (version
3.0; Ciphergen Biosystems). For identification of proteomic
profiles characteristic for inflammation (the MR score) and
bleeding (Hb peaks), examination of SELDI tracings was targeted
in 3 mass ranges: 3000 to 4000 Daltons (Da) (CHCA), 10 to 12.5
kiloDaltons (kDa) (SPA), 14 to 17 kDa (SPA). The data for the
biomarkers of the MR score were extracted from the 3000 to 4000
Da (P1 and P2, Figure 1A) and 10 to 12.5 kDa (P3 and P4,
Figure 1B) ranges. The data for the Hb peaks were extracted from
the 14 to 17 kDa region (Figure 1C). Both the MR score and Hb
profile provide qualitative information regarding the presence or
absence of intra-amniotic inflammation or bleeding, respectively
[5,6]. A categorical value of 1 is assigned if a biomarker peak is
present and 0 if absent. Thus, the MR score (inflammation) ranges
from 0 to 4, depending upon the presence or absence of each of
the four protein biomarkers and is a measure of the severity of
intra-amniotic inflammation. MR scores 3–4 are indicative of
severe inflammation. The Hb score (ranging from 0–2 depending
with the number of free Hb chains identified) indicates presence of
intra-amniotic bleeding for any value different than 0 [6]. The
generation of the MR and Hb scores for each SELDI tracing was
performed by an investigator who was blinded to the origins of the
amniotic fluid sample, clinical presentation, clinical outcome or
results of the placental histological examination.
Extraction of the proteomic pattern characteristic of
idiopathic preterm birth
A novel computational algorithm was employed to analyze the
proteomic information between 500 to 300,000 Da in our
experimental conditions. From a bioinformatics perspective,
SELDI tracings display silent areas alternating with hypervariable
areas. Silent areas are mass ranges devoid of proteomic
information and are identified by their similarity with the tracings
obtained with the PBS diluent alone. In contrast, hypervariable
Proteomics of Amniotic Fluid
PLoS ONE | www.plosone.org 2 April 2008 | Volume 3 | Issue 4 | e2049areas are the mass ranges rich in potential biomarker peaks and
are delineated by the high level of dissimilarity from the PBS
tracings. For the purpose of reducing complexity, our algorithm
first eliminated silent areas while extracting hypervariable areas.
We next performed a hierarchical clustering of the tracings based
on their similarity/dissimilarity in peaks present in hypervariable
areas. Presence or absence of peaks was converted to binary strings
with equal number of attributes and a hierarchical clustering
algorithm applied. From the several hypervariable areas analyzed,
we focused our attention on the mass area between 10 to 12.5 kDa
due to the non-random clustering of the tracings based on a
complex of five peaks in this region which we named the Q-
profile (Figure 2A). The peak components are labeled Q1–Q5.
Fluorescence two-dimensional differential gel
electrophoresis (2D-DIGE)
To clarify and expand the biological significance of the Q-
profile on a larger scale we employed 2D-DIGE on select pairs of
amniotic fluid samples matched for maternal age, parity,
gestational age at amniocentesis and membrane status. We used
amniotic fluid samples selected from patients with the Q-profile
who delivered preterm (n=3) and compared the results with
samples of amniotic fluid retrieved from women who presented
with symptoms of preterm labor but delivered at term (CRL,
n=3). 2D-DIGE was performed using the Ettan DIGE system
(GE Healthcare). Amniotic fluid proteins (67 mg) were labeled with
either Cy3 (Q-profile) or Cy5 (CRL). A reference pool (25 mg
total protein) was labeled with Cy2 and used as internal control.
For each pair, labeled samples were pooled and isoelectric focusing
was performed using an isoelectric point range of 3–10. SDS-
PAGE on a 12% gel was performed for the second dimension.
After spot detection, automatic background correction, spot
volume normalization and volume ratio calculation, dye ratios
were determined using DeCyder software (GE Healthcare). Spots
corresponding to $1.5-fold changes [13] were robotically excised
using the Ettan Spot Picker instrument (GE Healthcare) and
subjected to automated in-gel tryptic digestion on the Ettan TA
Digester (GE Healthcare). Automated MALDI-MS/MS spectra
were acquired on the 4800 TOF/TOF proteomics analyzer
(Applied Biosystems, Foster City, CA) and the resulting peptide
Figure 1. Proteomic patterns characteristic for intra-amniotic inflammation and bleeding. Three hypervariable areas of 4 representative
SELDI tracings of amniotic fluid (A: 3–4 kDa, B: 10–12.5 kDa and C: 14–17 kDa) are shown. These areas contain the proteomic patterns characteristic
of intra-amniotic inflammation (MR score composed of four protein biomarkers: P1: neutrophil defensin-2: P2: neutrophil defensin-1: 3448.09 Da, P3:
calgranulin C, P4: calgranulin A), intra-amniotic bleeding (Hb chains) or both (bottom tracins). The x-axis of the tracings represents the molecular
weight in Daltons; the y-axis represents the normalized peak intensity. R denotes a reference protein peak present in all fluid samples which
corresponds to a fragment of beta-2 microglobulin.
doi:10.1371/journal.pone.0002049.g001
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(Matrix Science, Boston, MA). The remaining aliquots of digests of
protein spots that were not identified by this approach were
subjected to LC/MS/MS analysis (Micromass Q-TOF) followed
by Sequest (Thermo Finnegan, San Jose CA) database searches.
Pathway analysis
Differentially expressed proteins were classified based on the
PANTHER (Protein ANalysis THrough Evolutionary Relation-
ships) system (http://www.pantherdb.org) [14]. PANTHER is a
unique resource that classifies genes and proteins by their
functions, using published scientific experimental evidence and
evolutionary relationships abstracted by curators with the goal of
predicting function even in the absence of direct experimental
evidence. Proteins are classified into families and subfamilies of
shared function, which are then categorized using a highly
controlled vocabulary (ontology terms) by biological process,
molecular function and molecular pathway.
Histological evaluation of the placenta
The diagnosis of histological chorioamnionitis was based on
neutrophil infiltration of the chorionic plate, amniochorionic
membranes and chorio-decidua. Three histological stages of
chorioamnionitis [15] (stage I: intervillositis, stage II: chorionic
inflammation, and stage III: full-thickness inflammation of both
chorion and amnion) were complemented by the histological
grading system devised by Salafia et. al. which includes four grades
of inflammation of the amnion, chorion-decidua and funistis [16].
Presence of hemosiderin in the placental basal plate, extraplacen-
tal membranes and decidua confirmed by iron stains was
suggestive of bleeding [17].
Immunoassays for interleukin-6 (IL-6) and matrix
metalloprotease-8 (MMP-8)
ELISA for human IL-6 (Pierce-Endogen, Rockford, IL) and
MMP-8 (R&D Systems, Minneapolis, MN) were performed in
duplicate by investigators unaware of clinical outcomes. Amniotic
fluid samples were diluted to allow for appropriate interpolation of
the results. The minimal detectable concentration for IL-6 was 1-
picogram/milliliter and less than 0.02-nanogram/milliliter for
MMP-8. The inter- and intra-assay coefficients of variation were
,10% for IL-6 and ,6% for MMP-8, respectively.
Statistical analysis
Data is presented as mean and standard deviation (SD) or, if
non-normally distributed, as median and range. Statistical analyses
were performed with Sigma Stat, version 2.03 (SPSS Inc.,
Chicago, IL). Data was compared with one-way ANOVA followed
by Student Newman Keuls tests (parametric) or Kruskal-Wallis on
ranks followed by Dunn’s tests (non-parametric), to adjust for
multiple comparisons as appropriate. Comparisons between
proportions were done with Chi-square or Fisher’s exact tests. A
p value of ,0.05 was considered significant.
Results
Description of a novel proteomic pattern (Q-profile)
associated with preterm birth in the absence of
inflammation and bleeding
Based on the established proteomic fingerprints of inflammation
and bleeding, we identified that of the 285 SELDI tracings
screened, 92 (32%) had either evidence of intra-amniotic
inflammation (n=71, MR 3-4), bleeding (n=6, Hb peaks present)
or both (n=15) (Figure 3). Application of the hierarchical
Figure 2. Biomarker peaks in the 10–12.5 kDa hypervariable region (Q-profile). A: Five SELDI peaks (Q1–Q5 denoted by green arrows) in
the 10–12.5 kDa mass region appeared in a subgroup of the SELDI tracings analyzed (Patients 1 and 2 are examples). The third tracing (Patient 3)
shows the lack of biomarkers in a woman that delivered at term. R denotes a reference protein peak present in all fluid samples which corresponds to
a fragment of beta-2 microglobulin. B: experimental masses (average and 95% confidence interval (95%CI) for the five biomarker components of the
Q-profile.
doi:10.1371/journal.pone.0002049.g002
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(no inflammation and no bleeding patterns) identified a novel
discriminatory profile consisting of 5 proteomic peaks in the 10–
12.5 kDa area of interest (Q-profile) (Figure 2A) in 32 patients. In
addition, peaks corresponding to those of the Q-profile were
found in 7 cases that also had inflammation and in one case where
bleeding coexisted with inflammation. The masses of the
biomarkers components of the Q-profile are listed in Figure 2B.
Clinical and outcome characteristics of women
displaying the novel proteomic pattern (Q-profile)
The cases displaying any type of amniotic fluid proteomic
fingerprint (n=124) had a significantly higher frequency of
preterm delivery (88%) compared to the rest (65%, p,0.001). To
further understand the biological significance of the Q-profile
we analyzed the cases that exclusively displayed this profile
(n=32) in comparison to four additional groups: those displaying
the inflammation fingerprint alone (n=64), the bleeding
fingerprint alone (n=6), the combined inflammation and
bleeding profile (n=14) and those displaying no proteomic
profile who delivered at term (n=33). In Table 1 we present the
demographical and outcome characteristics of these 5 groups of
women. As mentioned in Methods section, all women had clinical
signs and symptoms of preterm birth at the time of amniocentesis.
Women displaying either the Q-profile or the inflammation
profile were at an earlier gestational age at time of amniocentesis
compared to the reference group (ANOVA, p#0.001), but there
were no differences among the 4 groups that displayed any
proteomic profile. Women with the Q-profile presented more
often with intact membranes compared to the inflammation and/
or bleeding groups. Among the groups with abnormal proteomic
profiles, there was no significant difference in gestational age at
birth. However, a significantly higher proportion of women
displaying the bleeding and/or inflammation profile, underwent
an indicated preterm delivery subsequent to amniocentesis
results. Therefore, despite their expectant management, 84%
(27/32) of the women with the still Q-profile delivered
prematurely. The amniocentesis-to-delivery interval was longer
for women displaying the Q-profile as compared to those
displaying the proteomic fingerprint characteristic for inflamma-
tion and/or bleeding. Moreover, newborns in the inflammation
groups (with or without bleeding), but not those with the Q-
profile had significantly lower Apgar scores compared to all
other groups.
In Table 2 we present the results of the amniotic fluid analysis
for the 5 different groups. We determined that the Q-profile
group is characterized by amniotic fluid results similar to the group
with no profile and delivery at term.
8 All women displaying the Q-
profile had negative Gram stain, negative culture results and
normal levels of inflammatory cytokines. This was determined to
be in sharp contrast to the women who had the inflammation
profile present (with or without bleeding) who had significantly
lower glucose and elevated LDH activity, WBC, RBC counts and
elevated levels of IL-6 and MMP-8. The incidence of a positive
Gram stain and/or amniotic fluid culture result was also
significantly higher in the inflammation groups. The bleeding
alone group was characterized by elevated LDH activity levels in
the context of a higher RBC (but not WBC) count, and normal IL-
6 and MMP-8 levels.
The results of the pathologic examination of the placenta were
available in 101 of the cases in the 5 groups (Table 3). Overall, the
prevalence of histological chorioamnionitis (stages II-III) was 65%
(65/101). Similar to the group of women who delivered at term,
the women with the Q-profile had virtually no evidence of
chorioamnionitis, amnionitis or funisitis, despite delivering pre-
term. Lastly, bleeding was more frequently confirmed histologi-
cally in the context of bleeding-induced preterm birth (with and
without inflammation).
Based on these results we conclude that women displaying the
amniotic fluid Q-profile present most often with intact mem-
branes and are managed expectantly in the context of normal
amniotic fluid results. Yet, this group has a significantly higher risk
for preterm birth which typically occurs in the context of normal
placental histology. These findings concur with the concept that
the Q-profile is representative of an amniotic fluid proteomic
fingerprint which is different from that of the women with intra-
amniotic inflammation or bleeding. No clinical or biochemical
tests other than proteomic profiling of the amniotic fluid was able
to delineate this high-risk group of women.
Characterization of the amniotic fluid proteome
representative of women displaying the novel profile (Q-
profile)
Figure 4 shows a representative 2D-DIGE image of proteins
differentially expressed (red: spots up-regulated $1.5-fold, blue:
spots down-regulated$1.5-fold) between samples displaying the
Q-profile and reference samples amniotic fluid samples (matched
for gestational age at time of amniocentesis). Interestingly, more
Figure 3. Distribution of amniotic SELDI tracings based on proteomic patterns.
doi:10.1371/journal.pone.0002049.g003
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displaying the Q-profile rather than up-regulated (n=28). Of the
spots picked for identification, 22 matched to a protein in the
database with more than one peptide. Few spots matched to the
same NCBI GenID transcript number. In fact, a total of 17
distinct protein database matches appeared and were differentially
regulated at least 1.5-fold (Table 4) among the 2 groups. Further
data mining using the PANTHER classification system revealed
Table 1. Demographic and clinical characteristics of women displaying various proteomic fingerprints in amniotic fluid
Variable Q profile Inflammation Bleeding
Inflammation &
bleeding
None & term
delivery P value
n=32 n=64 n=6 n=14 n=33
Characteristics at amniocentesis
Age, years { 26 20–32 28 23–35 33 30–36 31 26–34 25 20–30 0.084
Gravidity { 2 1–3 2 1–4 3 2–3 3 2–3 2 1–3 0.754
Parity { 1 [0–1] 0 [0–1] 2 [0–2] 1 1–2 1 [0–1] 0.251
Non-Caucasian race { 20 (63) 47 (73) 2 (33) 9 (64) 24 (73) 0.279
History of preterm birth { 9 (27) 14 (35) 0 (0) 2 (14) 5 (16) 0.431
Gestational age, weeks 1 25642 7 642 6 662 7 643 0 64 ,0.001
Ruptured membranes { 3 (9) 29 (45) 3 (50) 12 (86) 0 (0) ,0.001
Uterine contractions { 16 (50) 36 (56) 1 (17) 7 (50) 13 (42) 0.342
Clinical chorioamnionitis { 1 (3) 11 (17) 0 (0) 1 (7) 2 (6) 0.144
Cervical dilatation { 1 [0–3] 2 [0–4] 1 [0–4] 1 [0–2] 0 [0–2] 0.023
Tocolysis { 12 (38) 24 (38) 0 (0) 8 (57) 13 (39) 0.209
Outcome characteristics
Amniocentesis-to-delivery, days { 40 [7–80] 1 [0–2] 2 1–8 0 [0–2] 55 [42–86] ,0.001
Gestational age at delivery, weeks { 33 26–35 27 24–31 31 23–33 28 25–31 39 37–39 ,0.001
Term delivery { 5 (16) 0 (0) 0 (0) 0 (0) 33 (100) ,0.001
Indicated preterm delivery { 5 (16) 42 (66) 4 (67) 11 (79) 0 (0) ,0.001
Birthweight, grams { 2,160 [1,088–2,401] 1,030 [750–1,513] 1,430 [769–1,902] 1,138 [755–1,580] 3,100 [2,854–3,476] ,0.001
Cesarean delivery { 10 (31) 28 (44) 2 (33) 5 (36) 3 (39) 0.915
Apgar score at 1 minute { 8 6–9 5 2–8 9 4–9 7 3–8 9 8–9 ,0.001
Apgar score at 5 minutes { 9 8–9 8 4–9 9 5–9 9 7–9 7 [9–8] ,0.001
{Data presented as median [interquartile range] and analyzed by Kruskal-Wallis ANOVA;
{Data presented as n (%) and analyzed by Chi square;
1Data presented as mean6SD and analyzed by One Way ANOVA.
doi:10.1371/journal.pone.0002049.t001
Table 2. Results of amniotic fluid analysis
Variable Q profile Inflammation Bleeding
Inflammation &
bleeding
None & term
delivery P value
n=32 n=64 n=6 n=14 n=33
Clinical laboratory analysis
Glucose, mg/dL { 30 23–36 7 2–18 17 7–28 4 2–13 34 [24–43] ,0.001
LDH, U/L { 155 [119–217] 619 [410–1475] 338 [171–1705] 456 [273–1312] 137 [102–171] ,0.001
WBC, cells/mm
3 { 3 1–5 700 [108–1,520] 10 1–21 755 [42–3750] 3 1–6 ,0.001
RBC, cells/mm
3 { 8 [3–90] 167 [17–1,006] 110 [23–160,338] 8,450 [400–312,000] 18 [7–217] ,0.001
Positive Gram stain { 0 (0) 27 (43) 1 (17) 5 (36) 0 (0) ,0.001
Positive cultures { 0 (0) 40 (63) 1 (17) 8 (57) 0 (0) ,0.001
Immunoassays
IL-6, ng/mL { 0.5 [0.2–1.2] 14.1 [6.0–43.8] 2.9 [1.3–4.8] 9.1 [5.5–15.9] 0.2 [0.1–0.2] ,0.001
MMP-8 ng/mL { 12.0 [3.9–22.4] 413.9 [178.5–1,087.5] 54.8 [19.2–68.9] 465.5 [75.2–411.9] 4.0 [2.7–5.6] ,0.001
{Data presented as median [interquartile range] and analyzed by Kruskal-Wallis ANOVA.
{Data presented as n (%) and analyzed by Chi square.
doi:10.1371/journal.pone.0002049.t002
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to 7 distinct and well-classified biological processes. The most
populated was protein metabolism (5/10 transcripts matched) and
signal transduction (3/10 transcripts matched) (Figure 5). PAN-
THER further converged the aberrantly expressed identities by
matching several transcripts to the same protein precursor in the
database (Table 5). This allowed us to conclude that the amniotic
fluids with Q-profile are characterized by up-regulation in insulin
growth factor binding protein (IGFBP-1), apolipoproteins (APO
A-I and APO A-IV), lumican and bikunin (alpha-1-microglobulin
light chain protein, complex-forming glycoprotein heterogeneous
in charge) and down-regulation in the anti-proteolytic factors
alpha-1-antitrypsin (SERPINA1), alpha-2-antiplasmin (SEPR-
PINF1, pigment epithelium derived factor) (Table 5).
Discussion
Employing multidimensional proteomics analysis of amniotic
fluid coupled with bioinformatic algorithms we were able to
identify a novel subgroup of patients at risk for preterm birth that
share common clinical, biochemical and proteomic features.
These cases were distinct from those characterized by intra-
amniotic inflammation or bleeding. The findings of the present
study further support the notion that preterm birth is the result of
several distinct pathogenetic pathways for which increased uterine
contractility, cervical ripening and/or PPROM are simply
common clinical features of the end product.
Proteomics encompasses protein separation and identification
techniques along with the necessary bioinformatic tools that allow
for biomarker discovery. Two current and rather opposing
proteomic approaches have emerged. One relies on generating
proteomic patterns from biological samples using high-throughput
mass spectrometry approaches while minimizing the need to know
the identity of the discriminatory biomarkers (proteomic pattern
diagnostic approach) [18]. The other focuses on identification of
proteins by digesting them into peptides and sequencing them
using tandem mass spectrometry and database searching (identi-
fication-centered proteomic approach) [19]. In several prior
studies, we and others have mined the amniotic fluid proteome
for combinations of biomarkers that would separate pathogenetic
pathways leading to preterm birth and could potentially be used as
predictors of outcome [10] In the present study we used a
multidimensional proteomic approach that combined SELDI-
based diagnostic pattern proteomics with identification-based
techniques (2D-DIGE) to find and understand changes in amniotic
fluid proteome associated with spontaneous preterm birth in the
absence of inflammation and bleeding. While in all prior studies
[5,6,10] the relevant proteomic profiles were derived by
comparing a ‘‘diseased set’’ versus a ‘‘normal set’’ as defined by
other non-proteomic clinical, biochemical or microbiological
criteria (differential proteomics), in the present study we used a
reverse approach. Since none of the current tools available in
clinical practice were of use to discriminate our patient pool
despite significant differences in their pregnancy outcomes we
sought to define a novel clinical instrument. After we eliminated
the proteomic tracings characterized by diagnostic patterns
indicative of the presence of inflammatory and bleeding, among
the remaining cases we found a distinct cluster of patients
characterized by presence of 5 SELDI peaks in the 10–12.5 kDa
region (Q-profile). By exploring the common clinical character-
istics of this subgroup we determined that these women presented
most often with preterm labor and intact membranes in the
context of normal amniotic fluid clinical and microbiological
results. However, the majority of cases in this subgroup delivered
prematurely despite tocolytic and expectant management per
standard protocols. To our knowledge the Q-profile is the first
proteomic pattern with the ability to identify women at risk for
Table 3. Results of histological analysis of the chorionic plate, placental membranes and umbilical cord.
Variable Q profile Inflammation Bleeding
Inflammation &
bleeding None & term delivery P value
n=18 n=58 n=5 n=14 n=6
Chorioamnionitis, stages II-III { 2 (11) 49 (84) 1 (20) 11 (79) 2 (33) ,0.001
Amnionitis, grades 2–4 { 2 (11) 43 (74) 1 (20) 10 (72) 1 (17) ,0.001
Choriodeciduitis, grades 2–4 { 7 (39) 54 (93) 1 (20) 12 (86) 2 (33) ,0.001
Funistits, grades 1–4 { 3 (15) 40 (69) 1 (20) 4 (31) 1 (17) ,0.001
Hemosiderin deposits present { 1 (6) 10 (17) 2 (40) 5 (38) 0 (0) ,0.001
{Data presented as n (%) and analyzed by Chi square.
doi:10.1371/journal.pone.0002049.t003
Figure 4. Representative two color merged 2D-DIGE image
with up or down-regulated proteins selected for identification.
Proteins in amniotic fluid with Q-profile present were labeled with Cy3
and proteins in control fluids with Cy5. Spots differentially regulated
($1.5 fold in log spot volume) were selected for identification. Spots
up-regulated are circled in red and spots down-regulated are circled in
blue.
doi:10.1371/journal.pone.0002049.g004
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bleeding.
With few exceptions, the current stage of medical practice
emphasizes disease classification based on shared clinical features
which together are representative of a syndrome. Assignment of
individual cases to these diagnostic categories frequently dictates
treatment choices. However, while in clinical instances such as
tumors or infectious etiologies the medical treatment is further
conditioned based on strict histopathologic or microbiologic
examinations, obstetrical practice lags seriously behind in this
respect. Perhaps, our failure to recognize and prevent preterm
birth rests with the inability to rapidly and accurately discern
Table 4. Differentially expressed proteins in amniotic fluid samples displaying the Q profile. Results of MS analysis
NCBI GenID Protein Identified
Matched
spots
Search
Score
Percent
Coverage
Peptides
matched
Fold
change
Up-regulated
gi|90108666 Chain C, Crystal Structure Of Lipid-Free Human
Apolipoprotein A-I
2 327 82 19 3.8
gi|223373 complex-forming glycoprotein heterogeneous in
charge (bikunin)
2 128 51 8 2.0
gi|61744449 insulin-like growth factor binding protein 1 isoform b precursor 3 181 33 6 2.0
gi|178779 apolipoprotein A-IV precursor 1 193 52 16 1.9
gi|642534 lumican 1 131 19 6 1.9
gi|4505047 lumican precursor 1 127 22 7 1.9
Down-regulated
gi|52695899 Chain L, Crystal Structure Of The Fab Yads1 Complexed
With H-Vegf
1 121 50 6 5.1
gi|7438712 Ig kappa chain NIG93 precursor-human 2 149 48 6 3.1
gi|34526394 unnamed protein product 1 90 29 5 2.9
gi|34531791 unnamed protein product 1 126 35 12 2.5
gi|10835794 Chain C, Crystal Structure Of The Fab Fragment Of A Human
Monoclonal Igm Cold Agglutinin
1 167 58 7 2.4
gi|5360679 anti-Entamoeba histolytica immunoglobulin kappa light chain 1 152 48 6 2.3
gi|29726975 Chain B, G-2 Glycovariant Of Human Igg Fc Bound To
Minimized Version Of Protein A Called Z34c
1 117 58 8 2.0
gi|1942629 Alpha1-Antitrypsin 1 216 55 17 1.8
gi|55641313 PREDICTED: similar to Serine (or cysteine) proteinase inhibitor,
clade A (alpha-1 antiproteinase, a (alpha1-antitrypsin)
1 116 39 16 1.7
gi|1144299 pigment epithelium-derived factor 1 83 26 7 1.7
gi|15825648 Chain K, Crystal Structure Of The Intact Human Igg B12 With
Broad And Potent Activity Against Primary HIV-1 Isolates
1 102 36 11 1.5
doi:10.1371/journal.pone.0002049.t004
Figure 5. Classification of the amniotic fluid proteome dys-regulated in samples expressing the Q-profile using the PANTHER
biological process classification system.
doi:10.1371/journal.pone.0002049.g005
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premature delivery. Personalized medicine, stands at the opposite
end of this ‘‘one size fits all’’ approach and relies heavily on
development of classification algorithms based on subclinical
features and biomarkers [20]. Nowhere is a ‘‘pathway specific
targeted treatment approach’’ more needed than in preventing
premature delivery and its consequences to the newborn baby. To
further identify novel pathways leading to preterm birth which
may allow for individualized targeted treatment we proceeded
with a proteomic identification-centered approach using the
classical differential proteomics paradigm by defining the ‘‘disease
set’’ as the samples expressing the Q-profile in the context of a
preterm delivery. In the current study we have determined that the
differentially expressed proteins which characterize the Q-profile
are primarily involved in protein metabolism, signal transduction
and transport. The identities of the proteins matched in the
database pointed to a metabolic rather than inflammatory
abnormality since none of the protein identities had apparent
inflammatory function.
APO A-I and APO A-IV are associated with high density
lipoprotein (HDL) and chylomicrons and have important roles in
cholesterol, trygliceride and phospholipid transport and metabo-
lism [21]. Most recently it has been proposed that APO A-IV is a
satiety factor acting centrally in the brain. In fasted young animals
there is a dramatic increase in liver mRNA synthesis and serum
levels of APO A-I and A-IV in response to glucocorticoids and
insulin increased by fasting stress [22]. APO A-I and A-IV have
been described previously in amniotic fluid, but to our knowledge
there has been no study investigating their levels or phenotypic
variants as it relates to the fetus and to preterm birth [23].
IGFBP-1 is the predominant insulin-like growth factor binding
protein in amniotic fluid [24]. It is produced by the decidua and
fetal liver and it is thought to play an important role in fetal growth
[25]. Higher mid-pregnancy levels of IGFBP-1 have been
associated with growth failure [26]. Using an in vitro model
Popovici et al demonstrated that hypoxia up-regulates fetal
hepatocyte IGFBP-1 mRNA steady-state levels and protein, which
is the major IGFBP derived from the fetal hepatocytes [27].
Another protein found differentially abundant in samples with the
Q-profile was lumican, a member of the small leucine-rich
proteoglycan family (SLRP) with important roles in embryonic
development, tissue repair, tumor growth, organization of
collagens [28] and maintenance of corneal transparency [29].
Bikunin (also known as the ‘‘complex-forming glycoprotein
heterogeneous in charge’’) is a Kunitz-type serin-protease inhibitor
predominantly found in amniotic fluid and to a lesser degree in
urine and serum where it circulates bound to the inter-alpha
inhibitor proteins [30] A number of studies have shown that many
serine protease inhibitors have complex effects on cellular growth
and differentiation unrelated to their anti-proteolytic function [31]
Bikunin in particular has the ability to modulate cell growth and to
block cellular calcium uptake and is currently being evaluated as a
novel anti-metastatic agent [32,33]. Additionally, bikunin has a
significant anti-inflammatory function by blocking systemic
cytokine induction in response to endotoxin challenge in vivo
[34] Finally, bikunin inhibits entotoxin-induced preterm labor in
mice, [35] inhibits prostaglandin expression from amnion cells
[36] suppresses uterine contractions [37] by reducing calcium
influx in myometrial cells [38] and suppresses premature cervical
ripening [39] which are all key pathogenetic processes necessary
for preterm birth. The observed upregulation in bikunin levels
may reflect an endogenous compensatory mechanism aimed to
prolong pregnancy and downplay inflammatory processes. This
may explain the longer duration to delivery in women with Q
profile compared to the other groups exhibiting abnormal
proteomic profiles, despite the similar gestational age at amnio-
centesis.
All proteins found differentially down-regulated in amniotic
fluid expressing the Q-profile (pigment epithelium-derived factor
[PEDF] and alpha-1 antitrypsin) were members of serpin
superfamily. The roles of these factors in amniotic fluid are not
well understood. PEDF is known to be the most potent inhibitor of
angiogenesis in the mammalian ocular compartment [40]. It also
has neurotrophic activity, both in the retina and in the central
Table 5. Classification and convergence of identified transcripts into PANTHER ontologies
Protein IDs PANTHER Best Hit PANTHER Biological Process
PANTHER
Pathway
PANTHER
Molecular Function
Up-regulated
NP_001013047 INSULIN-LIKE GROWTH FACTOR Signal transduction (ECM protein-mediated) PI3 kinase Miscellaneous function
NP_000587 BINDING PROTEIN 1 Homeostasis (growth factor)
NP_000030 APOLIPOPROTEIN A-I Lipid and fatty acid transport – Transporter
Transport Apolipoprotein
NP_000473 APOLIPOPROTEIN A-IV Lipid and fatty acid transport – Transporter
Transport Apolipoprotein
Blood circulation and gas exchange
NP_002336 LUMICAN Signal transduction (cell adhesion-mediated) – Receptor
Sensory perception (vision) ECM
NP_001624 ALPHA-1-MICROGLOBULIN/BIKUNIN Protein metabolism (proteolysis) – Serine protease inhibitor
Down-regulated
NP_001002235
NP_000286
NP_001002236
ALPHA-1-ANTITRYPSIN Protein metabolism (proteolysis) Coagulation Serine protease inhibitor
NP_002606 ALPHA-2-ANTIPLASMIN Protein metabolism (proteolysis) Coagulation Serine protease inhibitor
Abbreviations: ECM: extracellular matrix
doi:10.1371/journal.pone.0002049.t005
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senescent fibroblasts [40]. No prior study investigated the presence
PEDF in amniotic fluid or defined ‘‘normal levels’’. One study
found higher levels of trypsin activity and lower alpha 1-antitrypsin
concentration in amniotic fluid of women with PPROM [41] but a
subsequent study found no difference between amniotic fluid
alpha-1 antitrypsin in premature birth with intact versus ruptured
membranes or in those with intra-amniotic infection [42].
The present study demonstrates how diagnostic pattern
proteomics can be used in conjunction with identification-centered
proteomic techniques and bioinformatic tools to provide insight
into a problem which has frustrated clinicians for decades. We
acknowledge that at this time due to the limitation of the current
technology we have not been able to identify the specific proteins
responsible for the five SELDI peaks of the Q-profile.
Furthermore as SELDI and 2D-DIGE technologies are not
equivalent, the biomarker peaks comprising the Q profile may
not be part of the differentially expressed identities. Yet the SELDI
diagnostic pattern itself proved essential in isolating a subgroup of
preterm birth cases with unique features at the level of their
amniotic fluid proteome. This will perhaps prompt a future
research direction and paradigm into the prevention of prematu-
rity.
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